FTC Approves Final Order Settling Charges that Danaher Corporation’s Acquisition of GE Biopharma Was Anticompetitive

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Danaher Corporations acquisition of GE Biopharmawould likely reduce competition in highly concentrated markets that supply biopharmaceutical companies with key inputs.

Metadata
Provider: 
FTCFTC
URL: 
https://www.ftc.gov/news-events/press-releases/2020/05/ftc-approves-final-order-settling-charges-danaher-corporationshttps://www.ftc.gov/news-events/press-releases/2020/05/ftc-approves-final-order-settling-charges-danaher-corporations
Retrieved on: 
Friday, May 29, 2020
Information
Tags: 
Companies, Danaher Corporation, Federal Trade Commission, Sartorius AG, Sartorius, Rohit Chopra, General Electric, Danaher
Summary
Key Points: 
  • Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Danaher Corporations acquisition of GE Biopharmawould likely reduce competition in highly concentrated markets that supply biopharmaceutical companies with key inputs.
  • Danaher is divesting to Sartorius AG all rights and assets to research, develop, manufacture, market, and sell these products.
  • The Commission vote to approve the final order was 3-1-1, with Commissioner Rohit Chopra voting no and Commissioner Rebecca Kelly Slaughter not participating.
  • Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
Copyright: 
2020 FTC. All Rights Reserved.